Journal
JOURNAL OF HEPATOLOGY
Volume 56, Issue 6, Pages 1343-1350Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2012.01.009
Keywords
Hepatocellular carcinoma; Liver cancer; Histone modification; Signaling pathways; Molecular therapies
Categories
Funding
- Bayer Pharmaceutical
- NIH Institutes of Health [1RO1DK37340, 1RO1DK56621]
- US National Institutes of Diabetes and Digestive and Kidney Diseases [1R01DK076986-01]
- European Commission [259744]
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute [SAF-2010-16055]
- Landon Foundation-American Association for Cancer Research
- German Research Foundation (DFG)
- National Cancer Institute, Milan, Italy
- Instituto de Salud Carlos III
- ICREA Funding Source: Custom
Ask authors/readers for more resources
Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown. We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclinical models of liver cancer. Methods: Gene expression and copy number changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model. Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, respectively. Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy number gains. Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addition of sorafenib. Cell viability and proliferation declined, while apoptosis and autophagy increased. Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1. Combination therapy with panobinostat and sorafenib significantly decreased vessel density, and most significantly decreased tumor volume and increased survival in HCC xenografts. Conclusions: Aberrant expression of several HDACs and copy number gains of HDAC3 and HDAC5 occur in HCC. Treatment with panobinostat combined with sorafenib demonstrated the highest preclinical efficacy in HCC models, providing the rationale for clinical studies with this novel combination. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available